Trial
NCT01369875
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Metastatic Melanoma
Intervention
Cyclophosphamide
Why stopped
Premature closure. Protocol did not meet its primary objective.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-10